drugset / Trial / NCT04831996

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996

Phase 1 Completed 48 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.

Timeline

Start
2021-05-04
Primary completion
2022-07-08
Completion
2022-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule Oral

Indications